ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 176 filers reported holding ASCENDIS PHARMA A/S in Q4 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $6,456,896 | -12.2% | 60,221 | 0.0% | 0.01% | -16.7% |
| Q4 2022 | $7,354,791 | +22.5% | 60,221 | +3.6% | 0.01% | +20.0% |
| Q3 2022 | $6,002,000 | +26.2% | 58,127 | +13.6% | 0.01% | +42.9% |
| Q2 2022 | $4,757,000 | -18.5% | 51,174 | +1.7% | 0.01% | -12.5% |
| Q1 2022 | $5,836,000 | +17.4% | 50,305 | +36.2% | 0.01% | +33.3% |
| Q4 2021 | $4,970,000 | -11.5% | 36,943 | +4.8% | 0.01% | -33.3% |
| Q3 2021 | $5,618,000 | +87.5% | 35,248 | +54.7% | 0.01% | +125.0% |
| Q2 2021 | $2,997,000 | +10.4% | 22,780 | +8.2% | 0.00% | 0.0% |
| Q1 2021 | $2,714,000 | -57.1% | 21,057 | -44.4% | 0.00% | 0.0% |
| Q4 2020 | $6,320,000 | +105.5% | 37,894 | +95.5% | 0.00% | -20.0% |
| Q3 2020 | $3,076,000 | +17.3% | 19,388 | +9.4% | 0.01% | 0.0% |
| Q2 2020 | $2,622,000 | +52.4% | 17,729 | +21.9% | 0.01% | +25.0% |
| Q1 2020 | $1,720,000 | -14.7% | 14,538 | +0.3% | 0.00% | +33.3% |
| Q4 2019 | $2,016,000 | +44.6% | 14,492 | 0.0% | 0.00% | +50.0% |
| Q3 2019 | $1,394,000 | – | 14,492 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 11,225,357 | $1,001,863,112 | 18.92% |
| Q Global Advisors, LLC | 195,000 | $17,404 | 12.55% |
| Sofinnova Investments, Inc. | 754,032 | $67,297,356 | 4.41% |
| Avoro Capital Advisors LLC | 3,580,555 | $319,564,534 | 4.34% |
| Finepoint Capital LP | 139,772 | $12,474,651 | 4.32% |
| Spyglass Capital Management LLC | 657,853 | $58,713,380 | 4.24% |
| Saturn V Capital Management LP | 78,442 | $7,000,948 | 3.88% |
| DAFNA Capital Management LLC | 135,212 | $12,067,671 | 3.30% |
| ARS Investment Partners, LLC | 289,860 | $25,870,005 | 3.02% |
| Ghost Tree Capital, LLC | 100,000 | $8,925,000 | 2.95% |